Metastatic breast cancer

Susan G. Komen® Pushing for Public Policies to Eliminate Disparities in Breast Care Access

Retrieved on: 
Thursday, January 25, 2024
Mortality, Woman, Cancer, Patient, Public policy, House, Metastatic breast cancer, Legislation, Social, Life, Health equity, Senate, Medicare, Breast cancer, Metastasis, Diagnosis, Social Security Disability Insurance, Breast, MBC, Quality of life, Federation, Genetic testing, Mutation, Disease, Genetics, Access, Birth control

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, is committed to making health care more affordable and accessible to all, by passing state and federal legislation in 2024 to remove barriers that prevent people from receiving the timely and high-quality breast care they need.

Key Points: 
  • Public policies that remove ob­­­­­­stacles, such as the cost of care and when and where care is available, would make an immediate difference in mortality rates.
  • In fact, about one-third of breast cancer deaths could be prevented if everyone received the high-quality care that exists today.
  • Breast imaging, the most effective tool at detecting breast cancers, is available to most people yet is not accessible to all.
  • "Komen is approaching breast cancer comprehensively through diverse public policy initiatives, aiming to minimize the number of breast cancer deaths," Guthrie added.

New Novotech Report on Metastatic Breast Cancer Identifies 1,000 Clinical Trials Globally Since 2018

Retrieved on: 
Saturday, December 30, 2023
Clinical trial, Immunotherapy, Metastatic breast cancer, Breast cancer, Survival rate, Physician, Mortality, ROW, Optimism, Patient, Medicine, Birth control

The Metastatic Breast Cancer - Global Clinical Trial Landscape 2023 report found that there were over 1,000 clinical trials worldwide since 2018.

Key Points: 
  • The Metastatic Breast Cancer - Global Clinical Trial Landscape 2023 report found that there were over 1,000 clinical trials worldwide since 2018.
  • In addition, the report noted that “Out of 2.3 million global breast cancer cases, 0.67 million were identified as metastatic breast cancer, with Asia accounting for 45%, Western regions 35%, and the remaining regions 20%”.
  • Metastatic Breast Cancer, also known as Stage IV breast cancer, occurs when cancer cells from the breast spread to other parts of the body.
  • Despite advancements in screening and treatment, 20%-30% of those initially diagnosed with breast cancer progress to metastatic breast cancer, posing challenges with a 30% 5-year survival rate.

Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial

Retrieved on: 
Monday, November 6, 2023
Science, Breast, Report, ESMO, Progression-free survival, Therapy, Metastatic breast cancer, RL, Congress, European Society for Medical Oncology, Cyclin-dependent kinase 4, Conference, Breast cancer, Research, Cancer, Estrogen receptor alpha, Poster, JCO, Sheba Medical Center, ESR1, Fuchs, Prognosis, RM, Oncology, Estrogen, Clinical Cancer Research, Mortality, Patient, Fulvestrant, Mutation, Pharmaceutical industry, Medical imaging, Liquor, Woman, Incidence

The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.

Key Points: 
  • The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.
  • The case was previously presented as a poster and brief talk at the annual Metastatic Breast Cancer Research Conference in September 2022.
  • Topline results from the ELAINE-1 trial, including this patient, were reported at the European Society for Medical Oncology (ESMO) Congress 2022.
  • 5Jeselsohn R, De Angelis C, Brown M, et al: The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences

Retrieved on: 
Wednesday, October 18, 2023
Patient, Antibody, Metastatic breast cancer, Annual general meeting, Therapy, Breast cancer, BCT, TSX, Vaccine

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that BriaCell will be presenting at the following two upcoming scientific conferences.

Key Points: 
  • PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that BriaCell will be presenting at the following two upcoming scientific conferences.
  • The 2023 SITC 38th Annual Meeting will be taking place November 3-5, 2023 at San Diego Convention Center, San Diego, CA.
  • The 2023 San Antonio Breast Cancer Symposium® will be taking place December 5-9, 2023 at Henry B. Gonzalez Convention Center, San Antonio, TX.
  • Abstract Title: Analysis of Antibody Response to SV-BR-1-GM Therapeutic Vaccine in Breast Cancer Patients Using Human Protein Microarrays: Potential Correlations with Therapy Response
    Abstract Title: Randomized Phase 2 of Bria-IMT™, an Allogenic Human Cell Line with Antigen Presenting Activity, in Heavily Pretreated Metastatic Breast Cancer

Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference

Retrieved on: 
Tuesday, September 5, 2023
Therapy, Progression-free survival, ESR1, Metastatic breast cancer, Fulvestrant, Woman, Mutation, PFS, Trial of the century, Eli Lilly, ASCO, American Society of Clinical Oncology, Patient, Annual general meeting, Poster, Society, Conference, ORR, Pharmaceutical industry, Medical imaging, Lasofoxifene

COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it shared an encore poster presentation at the 10th annual Metastatic Breast Cancer Research Conference (MBCRC) highlighting the results of its Phase 2 ELAINE-2 clinical study.

Key Points: 
  • COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it shared an encore poster presentation at the 10th annual Metastatic Breast Cancer Research Conference (MBCRC) highlighting the results of its Phase 2 ELAINE-2 clinical study.
  • The poster, “ Lasofoxifene plus abemaciclib for treating ER+/HER2-, ESR1-mutated, metastatic breast cancer after progression on prior therapies: ELAINE-2 update ,” was presented Wednesday, Aug. 30.
  • Results were initially shared at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and updated in June at ASCO 2023.
  • With patient follow-up through Jan. 31, 2023, the combination of lasofoxifene and abemaciclib continued to be well-tolerated, with clinically meaningful efficacy in women with ER+/HER2- metastatic breast cancer and an ESR1 mutation.

THERESA'S RESEARCH FOUNDATION ANNOUNCES NEW WHITE PAPER AND CELEBRATES 10 YEARS OF BRINGING CANCER RESEARCHERS AND PATIENT ADVOCATES TOGETHER

Retrieved on: 
Monday, August 21, 2023
Steps, Linda, Mayo Clinic, University, Education, Friends, Accidental Death and Disability: The Neglected Disease of Modern Society, White paper, Johns Hopkins School of Medicine, Metastatic breast cancer, Cancer, Research, Doctor of Philosophy, Alvin J. Siteman Cancer Center, University of Utah, Basic research, Huntsman Cancer Institute, Professor, Patient, Breast cancer, Baylor College of Medicine, Odds, Friends of Cancer Research, Family, Conference, Nursing, Birth control, Pharmaceutical industry

This White Paper highlights Findings from the 2022 Metastatic Breast Cancer Research Conference and is a follow up to our publication in npj Breast Cancer .

Key Points: 
  • This White Paper highlights Findings from the 2022 Metastatic Breast Cancer Research Conference and is a follow up to our publication in npj Breast Cancer .
  • "Patient advocates and cancer researchers working together is critical for better research that leads to improved patient outcomes.
  • "I'm thrilled to welcome so many outstanding breast cancer researchers from across the world to the 10th annual Metastatic Breast Cancer Research Conference.
  • The Foundation will host a celebration to mark its 10-year milestone at this year's Metastatic Breast Cancer Research Conference in Park City, Utah on August 31.

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
PDAC, Completeness, Rochester, Trastuzumab, Pathology, Merck Group, Cash, Astrocyte, Patient, FCMI, Observation, H. Lee Moffitt Cancer Center & Research Institute, Private placement, Three Months, Eurosport 1, University, Brain, Research, Lecanemab, TME, Motivation, Drug discovery, Neoplasm, FDA, B cell, Safety, Cognition, Neuron, ICI, G protein-coupled receptor, Metastatic breast cancer, DC1, Cancer, Lung cancer, CCR8, Immunotherapy, Antibody, PFS, ARIA, Publication, MBC, Biomarker, Microglia, SEMA4D, Security, ORR, HD, Head and neck cancer, Drug development, Nature, SIGNAL, Avelumab, Neurodegenerative disease, Pfizer, CO, Breast cancer, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, HNSCC, Merck

ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs. .

Key Points: 
  • Expect to Complete 12-months treatment in June, 2024
    ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs.
  • Over the last few months, Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • In the first segment, completed on May 12, 2023, Vaccinex sold approximately 7.9 million shares of common stock for aggregate proceeds of $2.96 million.
  • For further details on Vaccinex’s financials, refer to its Form 10Q filed August 14, 2023 with the S.E.C.

George Clinical and EPS Collaborate on Important HR+/HER2- Breast Cancer Study in Asia Pacific

Retrieved on: 
Tuesday, June 27, 2023
Multicenter trial, AMED, Partnership, User experience, International, Progression-free survival, Metastatic breast cancer, Clinical trial, Pfizer, Research, Women's Community Cancer Project Mural, Language, PFS, Goserelin, Organization, HR, Patient, Randomness, Kidney, EPS, NCCH, Medical research, United States Army Medical Research and Development Command, Safety, Breast cancer, ATLAS, Pharmaceutical industry, Birth control, Woman, Tamoxifen

In 2016, among all the Clinical Research Core Hospitals in Japan, NCCH was selected by AMED (Japan Agency for Medical Research and Development) as one of the Global Clinical Trials Core Centers, focused on the reinforcement of facilitating international clinical trials in Japan between 2016-2018. This study is their first global investigator-initiated registration-directed trial (IIRDT) -- an important step toward the pursuit of the development of treatments and new drugs for the Asian population.

Key Points: 
  • In 2019 George Clinical and EPS formed a strategic partnership to help expand their operations across the Asia-Pacific region.
  • Since September 2019, EPS and George Clinical have been involved in a major study for the National Cancer Center Hospital, Japan (NCCH) on the clinical usefulness of a combination therapy in patients of any menopausal status with advanced or metastatic HR+/HER2- breast cancer.
  • George Clinical is entirely responsible for study execution in Singapore and Taiwan with specific duties including full study conduct, regulatory, safety reporting and site monitoring.
  • George Clinical's strong expertise in regulatory, site knowledge and oncology expertise in the Asia Pacific region add value to the EPS strengths in Japan.

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
CRC, Clinical trial, Maxima and minima, HER2, Nanakaly Hospital for Hematology & Oncology, Neoplasm, Trinket, Metastatic breast cancer, RECIST, Dragonfly, NK, Toxicity, NSCLC, Index, ASCO, Medical director, Patient, MBC, Cancer, Colorectal cancer, Infrared spectroscopy correlation table, Therapy, T, Safety, Nivolumab, Pharmaceutical industry, Medical imaging

WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago. The presentation, given by lead investigator Dr. Howard P. Safran, Chief of Hematology/Oncology at the Lifespan Cancer Institute and Medical Director for the Brown University Oncology Group, describes Dragonfly's Phase 1/2 clinical trial of its DF1001 HER2-targeting TriNKET®, a first-in-human study exploring the safety, tolerability, and preliminary biological and clinical activity of DF1001.

Key Points: 
  • WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago.
  • Single agent activity was seen in both HER2 high and HER2 low patients who previously progressed on prior HER2 directed therapies."
  • As of the April 14th data cutoff for ASCO presentation, Dragonfly has treated 106 patients with DF1001 monotherapy.
  • There are six Dragonfly developed drugs in the clinic – including DF1001.

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
CRC, Clinical trial, Maxima and minima, HER2, Nanakaly Hospital for Hematology & Oncology, Neoplasm, Trinket, Metastatic breast cancer, RECIST, Dragonfly, NK, Toxicity, NSCLC, Index, ASCO, Medical director, Patient, MBC, Cancer, Colorectal cancer, Infrared spectroscopy correlation table, Therapy, T, Safety, Nivolumab, Pharmaceutical industry, Medical imaging

WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago. The presentation, given by lead investigator Dr. Howard P. Safran, Chief of Hematology/Oncology at the Lifespan Cancer Institute and Medical Director for the Brown University Oncology Group, describes Dragonfly's Phase 1/2 clinical trial of its DF1001 HER2-targeting TriNKET®, a first-in-human study exploring the safety, tolerability, and preliminary biological and clinical activity of DF1001.

Key Points: 
  • WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago.
  • Single agent activity was seen in both HER2 high and HER2 low patients who previously progressed on prior HER2 directed therapies."
  • As of the April 14th data cutoff for ASCO presentation, Dragonfly has treated 106 patients with DF1001 monotherapy.
  • There are six Dragonfly developed drugs in the clinic – including DF1001.